Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 5101 to 5115 of 7688 results

  1. Vitamin D supplements in the management of CKD–mineral and bone disorders: In people with hyperparathyroidism secondary to CKD, does treatment with vitamin D or vitamin D analogues improve patient-related outcomes?

    Recommendation ID NG203/21 Question Vitamin D supplements in the management of CKD–mineral and bone disorders: In people with hyperparathyroidism

    Research recommendation
    Published
    30 September 2021

  2. Managing meningioma: immediate versus deferred radiotherapy for incompletely excised grade I meningioma:- Is immediate or deferred radiotherapy better for incompletely excised grade I meningioma?

    Recommendation ID NG99/5 Question Managing meningioma: immediate versus deferred radiotherapy for incompletely excised grade I meningioma:-

    Research recommendation
    Published
    11 December 2018

  3. What is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on treatment for adults with persistent nausea or vomiting not caused by chemotherapy which hasn't fully responded to optimised conventional antiemetics?

    Recommendation ID NG144/8 Question What is the clinical and cost effectiveness of cannabis-based medicinal products as an add-on treatment

    Research recommendation
    Published
    10 February 2020

  4. Techniques for confirming a diagnosis in people with suspected atypical Spitzoid melanocytic lesions: In people with reported atypical Spitzoid lesions, how effective are fluorescence in situ hybridization (FISH), comparative genomic hybridization (CGH) and tests to detect driver mutations compared with histopathological examination alone in predicting disease specific survival? This should be investigated ina prospective diagnostic study. Secondary outcomes should include sensitivity, specificity, accuracy, positive predictive value, disease specific survival and progression free survival.

    Recommendation ID NG14/07 Question Techniques for confirming a diagnosis in people with suspected atypical Spitzoid melanocytic lesions:

    Research recommendation
    Published
    4 August 2022

  5. Hysteroscopy compared with ultrasound or empiric pharmacological treatment in the diagnosis and management of heavy menstrual bleeding (HMB): -Is initial testing using hysteroscopy more effective than testing with pelvic ultrasound or empiric pharmacological treatment in the diagnosis and management of HMB?

    Recommendation ID NG88/1 Question Hysteroscopy compared with ultrasound or empiric pharmacological treatment in the diagnosis and management

    Research recommendation
    Published
    14 November 2018

  6. Is intravenous methylprednisolone more clinically and cost effective than oral methylprednisolone in people with relapsing–remitting Multiple Sclerosis (MS) and people with secondary progressive MS with continued relapses?

    Recommendation ID CG186/2 Question Is intravenous methylprednisolone more clinically and cost effective than oral methylprednisolone in

    Research recommendation
    Published
    9 June 2015

  7. Setting for induction of labour: Is it safe, effective and cost effective to carry out induction of labour in an outpatient setting? What are the advantages and disadvantages of such an approach, taking into account women's views?

    Recommendation ID NG207/07 Question Setting for induction of labour: Is it safe, effective and cost effective to carry out induction of

    Research recommendation
    Published
    15 December 2021

  8. Multiple pregnancy as an independent risk factor for pelvic floor dysfunction: Is multiple pregnancy an independent risk factor for pelvic floor dysfunction?

    Recommendation ID NG210/25 Question Multiple pregnancy as an independent risk factor for pelvic floor dysfunction: Is multiple pregnancy

    Research recommendation
    Published
    7 January 2022

  9. Neoadjuvant endocrine therapy in premenopausal women:- Is neoadjuvant endocrine therapy safe in premenopausal women with early breast cancer?

    Recommendation ID NG101/4 Question Neoadjuvant endocrine therapy in premenopausal women:- Is neoadjuvant endocrine therapy safe in premenopausal

    Research recommendation
    Published
    11 December 2018

  10. Pelvic floor muscle training for preventing pelvic floor dysfunction in older women: Is pelvic floor muscle training effective in preventing pelvic floor dysfunction for older women (aged 65 and over), and women in the perimenopausal or postmenopausal phases?

    Recommendation ID NG210/06 Question Pelvic floor muscle training for preventing pelvic floor dysfunction in older women: Is pelvic floor

    Research recommendation
    Published
    7 January 2022

  11. Pelvic floor muscle training for preventing pelvic floor dysfunction in young women: Is pelvic floor muscle training for young women (between 12 and 17 years) effective in preventing pelvic floor dysfunction?

    Recommendation ID NG210/02 Question Pelvic floor muscle training for preventing pelvic floor dysfunction in young women: Is pelvic floor

    Research recommendation
    Published
    7 January 2022

  12. Is primary radical cystectomy more effective than primary intravesical BCG (Bacille Calmette-Guérin) in high risk non-muscle-invasive bladder cancer, in terms of quality of life and cancer-specific outcomes?

    Recommendation ID NG2/2 Question Is primary radical cystectomy more effective than primary intravesical BCG (Bacille Calmette-Guérin) in

    Research recommendation
    Published
    9 June 2015

  13. There is uncertainty about how much remote monitoring devices would affect resource use in the NHS and personal social services. Some impacts may not have been included in the external assessment group's (EAG) model because of a lack of data (see section 3.12 ), including resource use related to carers (see section 3.13 ). Adopting the technologies may change how care is provided (see section 3.4 ) so their effect on resources is hard to estimate without direct data. So, the committee recommended collecting data on how much using the devices affects resource use, to inform cost-effectiveness estimates. Data on time dedicated to training and spent reviewing device results should also be collected. The broader impact on services provided by Parkinson's specialist teams and carers should be considered.

    Recommendation ID DG51/01 Question There is uncertainty about how much remote monitoring devices would affect resource use in the NHS and

    Research recommendation
    Published
    7 March 2023

  14. What is the clinical effectiveness of preoperative nasal decolonisation using mupirocin in combination with a chlorhexidine body wash in the whole population?

    Recommendation ID NG125/1 Question What is the clinical effectiveness of preoperative nasal decolonisation using mupirocin in combination

    Research recommendation
    Published
    16 August 2019

  15. How much using remote monitoring devices to guide decisions about care affects symptoms, and therefore health-related quality of life, is uncertain. How long after using the devices any impact would last is also uncertain. This had a sizeable influence on cost-effectiveness estimates (see section 3.10 ). Data on this came from studies that did not represent likely NHS practice (see section 3.6 ), which is itself uncertain (see section 3.3 ), and from assumptions made by the EAG because of lack of data. For its model, the EAG used a published algorithm from Chandler et al. (2020) to estimate quality-adjusted life years (QALYs) from the Unified Parkinson's Disease Rating Scale (UPDRS) domain scores. The clinical experts said that health-related quality of life questionnaires like the PDQ‑39 are increasingly used in trials to assess health-related quality of life for people with Parkinson's disease. The committee also recognised that the effect of the devices on the health-related quality of life of carers had not been included in the EAG's model because of a lack of data (see section 3.13 ).

    Recommendation ID DG51/02 Question How much using remote monitoring devices to guide decisions about care affects symptoms, and therefore

    Research recommendation
    Published
    7 March 2023